skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Currently there are no approved pharmacologicaltreatments for non-alcoholic fatty liver disease(NAFLD), including the subtype non-alcoholicsteatohepatitis (NASH). The prevalence of thedisease is on the rise, as are common comorbiditiessuch as diabetes, insulin resistance and obesitythat contribute to this disease. NAFLD is a leadingcause of liver disease and can potentially result inhepatocellular carcinoma (HCC).

 

Over the past fewyears there has been increased interest from ourTrialtrove clients for clinical trials intelligence on thetreatment of (NAFLD), including the subtype (NASH).In the following report, I will leverage Trialtrovedata to assess the current industry sponsored trialslandscape, including patient demographics, triallocations and which pharmaceutical companies arebest positioned to enter the NAFLD market.

As of February 2017, Trialtrove has captured 594 trials for symptom relief and/or the treatment, modification, or cure of NAFLD.

 

Download the Whitepaper to find out more about the trials now

NAFLD whitepaper download

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: